Regeneron Genetics Center marks 14 years of operations as the company pivots toward the potential of artificial intelligence in drug development. By building a massive genetic database, the research unit focuses on target validation, a critical step in identifying successful medical treatments.
Chief business and administrative officer Andy Deubler recently discussed the role of the center within the larger Regeneron model. He notes that the ability to interpret deep troves of data provides a distinct advantage in current pharmaceutical research.
This genetic research directly informs clinical successes. The team point to the development of the hearing loss gene therapy Otarmeni as a primary example of how their data-driven approach translates to real-world medical breakthroughs.
As the company moves into new technological frontiers, the focus remains on scaling its genetic library. The integration of high-level machine learning allows researchers to process information at speeds that were not possible even a few years ago. This expansion positions the center to remain a central player in genetic medicine for the foreseeable future.